6 results about "Leukemia Stem Cell" patented technology

The present disclosure provides methods of treating acute myeloid leukemia (AML) and determining responsiveness to an AML treatment regimen, which methods involve identifying the presence or absence of myeloid / lymphocytic leukemia stem cells (M / L LSCs) in a sample from a subject.

The application belongs to the technical field of biological medicine, and particularly relates to application of a flavone small molecule compound in preparation of a drug for regulating WDR1 and / or treating leukemia. The flavone small molecule compound comprises Gambogic amide, Morellic acid, Flavopiridol hydrochloride, Gambogic Acid and / or Methylophiopogonanone B. The application research finds that the flavone small molecule compound such as Gambogic amide can effectively inhibit the activity of acute myeloid leukemia stem cells, and does not damage normal hematopoietic stem cells. The flavone small molecule compound is combined with WDR1 protein specifically expressed in the leukemia stem cells, induces cytoskeleton depolymerization, and further promotes the occurrence of leukemia stem cell apoptosis. The application provides a new direction for prevention and treatment of AML.

The application belongs to the technical field of biological medicine, and particularly relates to application of PADI2 inhibitor combined with BCL-2 inhibitor in treatment of acute myeloid leukemia. The application proves for the first time that PADI2 presents high expression in acute myeloid leukemia and is significantly related to poor prognosis of patients. Functional research shows that PADI2 is necessary for occurrence of acute myeloid leukemia and maintenance of leukemia stem cells, but is not necessary for normal hematopoietic process. In a treatment strategy, PADI2 inhibitor combined with BCL-2 inhibitor venetoclax shows a significant synergistic anti-leukemia effect and can effectively inhibit AML progression. The research not only establishes PADI2 as a potential target for treatment of acute myeloid leukemia, but also provides a theoretical basis for combined use of PADI2 inhibitor and BCL-2 inhibitor venetoclax, opens a new direction for improving the efficacy of acute myeloid leukemia, and therefore has important clinical significance and social value.

The invention relates to a method for targeted delivery of miR-21 molecules to CD34 + CD38-LSCs by using exosomes derived from leukemia stem cells (LSCs) to enhance the dryness of the leukemia stem cells and significantly enhance the proliferation capacity and multidirectional differentiation potential of the LSCs in in-vivo and in-vitro dual models. The technology provides an innovative solution for functional regulation and control, in vitro amplification and regenerative medicine application of leukemia stem cells.